A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 35/76 (2006.01) A61K 39/285 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2681096
Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject administered at least 1 x 108 viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
Cette invention se rapporte à des procédés comprenant un virus de la vaccine déficient en thymidine kinase. Les procédés comprennent l'administration du virus de la vaccine à des concentrations virales accrues. D'autres aspects de l'invention comprennent des procédés permettant d'induire le phénomène d'oncolyse ou de suppression du réseau vasculaire tumoral chez un sujet atteint d'une tumeur, lesdits procédés comprenant l'administration au dit sujet d'au moins 1 x 108 particules virales d'un vecteur du virus de la vaccine déficient en TK, exprimant le GM-CSF, capable de se répliquer, suffisant pour induire l'oncolyse des cellules de la tumeur.
Jennerex Inc.
Smart & Biggar
LandOfFree
Oncolytic vaccinia virus cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oncolytic vaccinia virus cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oncolytic vaccinia virus cancer therapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1808577